Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, open-label, multicenter Phase II study designed to evaluate the safety and efficacy of selinexor versus physician's choice (PC) in patients with Myelofibrosis who had at least six months of treatment with a JAK1/2 inhibitor

Next Previous
X
Search
Trial Profile

A randomized, open-label, multicenter Phase II study designed to evaluate the safety and efficacy of selinexor versus physician's choice (PC) in patients with Myelofibrosis who had at least six months of treatment with a JAK1/2 inhibitor

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Selinexor (Primary)
  • Indications Myelofibrosis
  • Focus Therapeutic Use

    • Most Recent Events

    • 23 Aug 2021 According to an Antengene Corporation media release, this trial will be conducted at 15 centers across China, including the primary trial center the First Affiliated Hospital Soochow University, and will enroll approximately 20 patients in total.
    • 23 Aug 2021 According to an Antengene Corporation media release, the China National Medical Products Administration has approved this Phase II study of selinexor for the treatment of patients with myelofibrosis (MF).
    • 09 Jul 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top